Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 1,970,000 shares, a drop of 16.9% from the April 30th total of 2,370,000 shares. Approximately 4.1% of the shares of the company are short sold. Based on an average trading volume of 2,520,000 shares, the short-interest ratio is currently 0.8 days.
Milestone Pharmaceuticals Stock Performance
MIST stock traded down $0.01 during midday trading on Friday, hitting $1.73. The stock had a trading volume of 534,958 shares, compared to its average volume of 918,331. Milestone Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $2.75. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. The stock has a 50-day simple moving average of $1.18 and a 200 day simple moving average of $1.69. The firm has a market capitalization of $92.49 million, a price-to-earnings ratio of -2.14 and a beta of 0.92.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). As a group, equities research analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities analysts recently commented on MIST shares. TD Securities cut shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. TD Cowen downgraded shares of Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 1st. HC Wainwright started coverage on shares of Milestone Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $5.00 price objective for the company. Finally, Cowen cut shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Milestone Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $7.00.
Get Our Latest Research Report on Milestone Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp grew its stake in shares of Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after purchasing an additional 10,000 shares during the period. National Bank of Canada FI raised its position in Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock valued at $44,000 after purchasing an additional 11,600 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Milestone Pharmaceuticals in the fourth quarter worth $73,000. XTX Topco Ltd bought a new stake in shares of Milestone Pharmaceuticals during the fourth quarter worth $80,000. Finally, Northern Trust Corp increased its stake in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after buying an additional 30,772 shares in the last quarter. Institutional investors and hedge funds own 86.18% of the company's stock.
Milestone Pharmaceuticals Company Profile
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Read More
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
